Key findings Across all four trials, GLP-1 RAs were consistently associated with lower rates of alcohol-related hospitalization within one year in balanced populations: ADM trial (n = 18,515) : Alcohol-related hospitalization occurred in 10.1% of newer GLP-1 RA users vs
In contrast, berberine patches lack comparable evidence
A meta-analysis by Faraone and Buitelaar (2010) pooling data from multiple randomized controlled trials found that amphetamine-based medications had a modestly larger mean effect size (SMD 0.99) for ADHD symptom reduction compared to methylphenidate-based medications (SMD 0.78) [6]
The increasing use of GLP-1 medications for adolescent obesity opens up new avenues for managing a complex chronic condition, but it also raises important questions about long-term implications
While clinical trials have provided valuable insights, further research is should determine the optimal use of these agents in different heart failure populations
Fibrosis was evaluated applying the Kleiner classification (f0f4) 50
